Replies to post #465856 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Donnenamab had 3 brain bleed deaths directly related to drug (16 deaths in total in drug group including those not related to drug from n853 who started on the drug). Also 13 dosed particiants had serious symptoms relating to brain swelling. This still got FDA approved though.

Blarcamsine had 1 death not related to drug out of n 335 who started on the drug. Would rather have the dizziness and slightly higher drop out rate at the beginning then potential brain bleed.

The drop out rate for blarcamesine clearly diminshed as time went on for those on the drug with no drop outs between weeks 36 and 48 even for 50mg group. So those who were happy to stay on the drug clearly benefited versus those still on placebo. Also it sounds like from the presentation that they have had better success with nighttime dosage.

[tradeherpete]

No, with the high dropout rate in the placebo group it looks like this fragile group of participants had other things going on.

Covid was ruled out in some dropout cases but the drug doesn't automatically become suspect as further inspection reveals.

Alzheimer's patients have more challenges than most, for them to continue to take the drug while experiencing dizziness is a lot to ask.

But as Ern Heaven pointed out in his video, the experience of slipping into the netherworld of Alzheimer's wasn't pleasant either.

Does anyone have a link to the Ern Heaven video? I think it would be helpful to review that, it's been so long since we've seen it.

Then, after watching Ern a few times, I urge you to continue your crusade extolling the safety of Mab drugs.